Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01501266
NCT01501266
Completed
Not Applicable

Faslodex Specific Clinical Experience Investigation for Long-term Use

AstraZeneca1 site in 1 country660 target enrollmentFebruary 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
AstraZeneca
Enrollment
660
Locations
1
Primary Endpoint
Incidence of serious adverse events.
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to confirm the safety profile such as the frequency of serious adverse events or any unexpected adverse events and overall efficacy of Faslodex for long term treatment in daily clinical practice.

Detailed Description

MC MD

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
January 2015
Last Updated
9 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients treated with Faslodex for the first time due to postmenopausal breast cancer

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Incidence of serious adverse events.

Time Frame: 1 Year

Incidence of adverse drug reactions.

Time Frame: 1 year

Secondary Outcomes

  • Incidence of adverse drug reactions with injection site reaction, thromboembolic events and hepatic impairment(1 year)
  • Progression-free survival(1 year)

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Not Applicable
Faslodex Observations During Regular Use by Advanced Mammacarcinoma PatientsBreast Cancer
NCT00241462AstraZeneca150
Completed
Not Applicable
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in FranceBreast Cancer
NCT00681369AstraZeneca217
Active, not recruiting
Not Applicable
Clinical study for the assessment of safety and efficacy of Bezafibrate as a drug therapy for patients suffering from an inborn muscular dysfunction characterized by intramuscular lack of energy supplymitochondrial disorderTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2012-002692-34-ATniv.-Klinik für Kinder- und Jugendheilkunde16
Completed
Not Applicable
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)Malignant Neoplasm of Breast Stage IV
NCT01509625Isabel Blancas272
Recruiting
Not Applicable
Resuscitative TEE Collaborative RegistryCardiac ArrestCardiac Arrest CirculatoryCardiac Arrest, Out-Of-HospitalShockHemodynamic Instability
NCT04972526University of Pennsylvania1,000